RecruitingPhase 1Phase 2NCT06883526

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Enrollment

60 participants

Start Date

May 16, 2025

Study Type

INTERVENTIONAL

Conditions

Lymphoma

Summary

PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of two experimental drugs — ZG005 and gecacitinib — in people with lymphoma (a cancer of the lymphatic system) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with lymphoma confirmed by biopsy - Your lymphoma has relapsed (come back) or is refractory (no longer responds to treatment) **You may NOT be eligible if...** - Your lymphoma has spread to the brain or central nervous system - You have severe heart or brain/vascular disease - The study doctor determines you are not suitable for participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALZG005 for Injection

intravenous infusion

DRUGGecacitinib Hydrochloride Tablets

Oral

Locations(1)

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06883526

Related Trials

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

NCT068562261 location

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT045704235 locations